Autres langues Vertex Pharmaceuticals Incorporated

Actions

VRTX

US92532F1003

Produits pharmaceutiques

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 26/06/2026			Varia. 5j.	Varia. 1 janv.
491,34 ^USD	+2,32 %		+8,79 %	+8,38 %

24/06	Et si le marché signalait une pause du rally IA pour l'été ?
23/06	Et si le marché nous indiquait clairement une pause du rally "IA" pour l'été ?

Autres langues

25/06	KI-Rally - signalisiert der Markt eine Sommerpause?
24/06	Geeft de markt het signaal voor een zomerpauze in de AI-rally?
24/06	¿Anticipa el mercado una suspensión del rally de la IA durante el verano?
24/06	What if the market is signaling a clear pause in the AI rally for the summer?
22/06	Proteome contract win; Eco Buildings milestone
17/06	Vertex Pharmaceuticals Insider Sold Shares Worth $1,827,900, According to a Recent SEC Filing
11/06	Vertex's Late-Stage Clinical Data of Casgevy Deliver Crisis-Free, Transfusion-Free Results in Kids With Blood Disorders
11/06	Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions
11/06	Vertex Pharmaceuticals Incorporated Presents New Data on Casgevy and Announces Additional Global Regulatory Submissions
09/06	Vertex Pharmaceuticals Insider Sold Shares Worth $785,250, According to a Recent SEC Filing
09/06	Münchner Biotechfirma erhält Zulassung für neuartiges Cannabis-Schmerzmittel
05/06	Vertex Pharmaceuticals Incorporated Presents New Data On ALYFTREK And TRIKAFTA At European Cystic Fibrosis Conference
05/06	Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference
05/06	Compañías que se deben tener muy en cuenta por técnico este viernes
05/06	Worldwide Healthcare Trust outperforms benchmark; praises AstraZeneca
05/06	Valores destacados al cierre del mercado norteamericano
04/06	Otsuka says kidney disease drug preserves function in late-stage study
03/06	Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10
02/06	Vertex Pharmaceuticals Insider Sold Shares Worth $888,300, According to a Recent SEC Filing
01/06	Vertex announces US FDA acceptance of biologics license application for accelerated approval of povetacicept in IgA nephropathy
01/06	Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy
01/06	Vertex Pharmaceuticals Incorporated Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy
21/05	Vertex Pharmaceuticals Says New Pain Management Drug Is Under Review at Health Canada
21/05	Vertex Says Health Canada Accepts Suzetrigine Application for Review
21/05	Vertex Pharmaceuticals Announces New Drug Submission for Suzetrigine Accepted for Review by Health Canada